공시 • Mar 13
Corentec Co., Ltd., Annual General Meeting, Mar 27, 2026 Corentec Co., Ltd., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 12, yeongsanhong 1-gil, ipjang-myeon, seobuk-gu, chungcheongnam-do, cheonan South Korea Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to ₩5,490, the stock trades at a trailing P/E ratio of 47.4x. Average trailing P/E is 19x in the Medical Equipment industry in South Korea. Total loss to shareholders of 50% over the past three years. New Risk • Dec 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩87.1b market cap, or US$59.2m). Valuation Update With 7 Day Price Move • Dec 08
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩6,810, the stock trades at a trailing P/E ratio of 58.8x. Average trailing P/E is 20x in the Medical Equipment industry in South Korea. Total loss to shareholders of 31% over the past three years. New Risk • Aug 16
New major risk - Revenue and earnings growth Earnings have declined by 31% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩75.3b market cap, or US$54.2m). New Risk • Mar 28
New major risk - Revenue and earnings growth Earnings have declined by 24% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 24% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩79.0b market cap, or US$53.9m). 공시 • Mar 13
Corentec Co., Ltd., Annual General Meeting, Mar 28, 2025 Corentec Co., Ltd., Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 12, yeongsanhong 1-gil, ipjang-myeon, seobuk-gu, chungcheongnam-do, cheonan South Korea New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩70.8b market cap, or US$49.3m). Reported Earnings • Nov 20
Third quarter 2024 earnings released: ₩70.00 loss per share (vs ₩113 profit in 3Q 2023) Third quarter 2024 results: ₩70.00 loss per share (down from ₩113 profit in 3Q 2023). Revenue: ₩22.0b (down 7.0% from 3Q 2023). Net loss: ₩897.3m (down 162% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩6,350, the stock trades at a trailing P/E ratio of 28.2x. Average trailing P/E is 16x in the Medical Equipment industry in South Korea. Total loss to shareholders of 62% over the past three years. New Risk • May 25
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 1.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.6x net interest cover). Minor Risk Market cap is less than US$100m (₩107.4b market cap, or US$78.7m). New Risk • Apr 05
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩132.0b (US$97.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (3.3% increase in shares outstanding). Market cap is less than US$100m (₩132.0b market cap, or US$97.8m). New Risk • Oct 26
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩135.1b (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (3.3% increase in shares outstanding). Market cap is less than US$100m (₩135.1b market cap, or US$99.5m). 공시 • May 18
Corentec Co., Ltd. announced that it has received KRW 1.19999236 billion in funding On May 17, 2023, Corentec Co., Ltd. closed the transaction. 공시 • May 11
Corentec Co., Ltd. (KOSDAQ:A104540) acquired 80% stake in Woosung Pharma Inc. Corentec Co., Ltd. (KOSDAQ:A104540) acquired 80% stake in Woosung Pharma Inc. for KRW 7.2 billion on May 9, 2023. Corentec will acquire 92.34 million shares in Woosung Pharma.
Corentec Co., Ltd. (KOSDAQ:A104540) completed the acquisition of 80% stake in Woosung Pharma Inc. on May 9, 2023. 공시 • May 10
Corentec Co., Ltd. announced that it expects to receive KRW 1.19999236 billion in funding Corentec Co., Ltd announced a private placement of 102,214 common shares of par value KRW 500 per share at an issue price of KRW 11,740 per share for gross proceeds of KRW 1,200,000,000 on May 9, 2023. The transaction will include participation from new investor Hwan-woo Cho. The company will issue securities through third party allotment method. All securities to be issued will be subject to a lock-up period of one year. The transaction has been approved by the board of directors of the company and is expected to close on May 17, 2023. 공시 • Feb 08
Corentec Appoints Michael Son as Executive Vice President Corentec has re-hired Michael Son to lead its sales and business development operations in the Americas, as Executive Vice President. Son will be responsible for pricing strategies, negotiations, hiring, and P&L, and will report to Corentec’s three Co-CEO’s, the Sun Brothers. Son, who was previously with Corentec from 2011 to 2015 as Vice President of Sales, brings more than 25 years of medical device sales experience where he worked with both large and small/start-up orthopedic companies in the European, Asia-pacific, U.S. and South America markets. Son is a highly strategic and influential medical device sales leader who will play an important role in building and strengthening relations between Corentec’s Korean operations and the Americas. Son holds a Bachelor of Arts Degree from University of Waterloo in Ontario, Canada, and is a graduate of the Executive Business Management program and National University of Singapore. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • May 17
First quarter 2021 earnings released The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: ₩10.6b (up 6.7% from 1Q 2020). Net income: ₩953.1m (up 1.1% from 1Q 2020). Profit margin: 9.0% (in line with 1Q 2020). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Feb 25
New 90-day high: ₩18,800 The company is up 50% from its price of ₩12,500 on 27 November 2020. The South Korean market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 2.0% over the same period. Valuation Update With 7 Day Price Move • Feb 25
Investor sentiment improved over the past week After last week's 20% share price gain to ₩18,800, the stock is trading at a trailing P/E ratio of 69.8x, up from the previous P/E ratio of 58.1x. This compares to an average P/E of 18x in the Medical Equipment industry in South Korea. Total returns to shareholders over the past three years are 50%. Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment improved over the past week After last week's 23% share price gain to ₩16,600, the stock is trading at a trailing P/E ratio of 61.6x, up from the previous P/E ratio of 50.3x. This compares to an average P/E of 20x in the Medical Equipment industry in South Korea. Total returns to shareholders over the past three years are 32%. Valuation Update With 7 Day Price Move • Dec 30
Investor sentiment improved over the past week After last week's 21% share price gain to ₩17,400, the stock is trading at a trailing P/E ratio of 64.6x, up from the previous P/E ratio of 53.5x. This compares to an average P/E of 20x in the Medical Equipment industry in South Korea. Total returns to shareholders over the past three years are 26%. Is New 90 Day High Low • Dec 21
New 90-day high: ₩15,150 The company is up 66% from its price of ₩9,120 on 22 September 2020. The South Korean market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 2.0% over the same period. Valuation Update With 7 Day Price Move • Nov 11
Market bids up stock over the past week After last week's 19% share price gain to ₩10,800, the stock is trading at a trailing P/E ratio of 39.3x, up from the previous P/E ratio of 33x. This compares to an average P/E of 20x in the Medical Equipment industry in South Korea. Total return to shareholders over the past three years is a loss of 15%. Is New 90 Day High Low • Nov 10
New 90-day high: ₩9,490 The company is up 13% from its price of ₩8,400 on 12 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is flat over the same period. 공시 • Nov 05
Corentec Co., Ltd. announced that it expects to receive KRW 15 billion in funding from Pureun Partners Asset Management Corentec Co., Ltd. (KOSDAQ:A104540) announced a private placement of 8th registered unsecured unguaranteed private convertible bonds for gross proceeds of KRW 15,000,000,000 on November 3, 2020. The bonds will not bear any interest and will have a yield to maturity of 0%. The bonds will mature on December 4, 2025. The bonds will be convertible into common shares at a fixed conversion price of KRW 8,900 per share between December 4, 2021 and November 4, 2025. The transaction has been approved by the board of the company. The payment date is December 4, 2020. The transaction will include participation from Pureun Partners Asset Management for KRW 15,000,000,000.